Traduction de «after breast cancer » (Néerlandais → Français) :

L. Holmberg en H. Anderson: HABITS (hormonal replacement therapy after breast cancer - is it safe?), a randomised comparison: trial stopped.
L. Holmberg et H. Anderson: HABITS (hormonal replacement therapy after breast cancer - is it safe?); a randomised comparison: trial stopped.

Lancet 363, 453-455 (2004) R.T. Chlebowski en N. Col (Commentary): Menopausal hormone therapy after breast cancer.
Lancet 363, 453-455 (2004) R.T. Chlebowski et N. Col (Commentary): Menopausal hormone therapy after breast cancer.

Ook de Beautiful After Breast Cancer Fundation organiseert activiteiten ter gelegenheid van BRA Day.
The Beautiful After Breast Cancer Fundation organise également des activités à l’occasion du BRA Day.

19. Miller AB, To T, Baines CJ, Wall C. The Canadian National Breast Screening Study-1: breast cancer mortality after 11 to 16 years of follow-up.
20. Miller AB, To T, Baines CJ, Wall C. The Canadian National Breast Screening Study-1: breast cancer mortality after 11 to 16 years of follow-up.

50. Miller Ab TTBCJWC. The Canadian National Breast Screening Study-1: breast cancer mortality after 11 to 16 years of follow-up.
49. Miller Ab TTBCJWC. The Canadian National Breast Screening Study-1: breast cancer mortality after 11 to 16 years of follow-up.

In August 2009, “The New England Journal of Medicine” published results from the landmark BIG 1-98 study affirming that the five-year upfront use of Femara after surgery was an optimal treatment approach for postmenopausal women with early-stage, hormonereceptor positive breast cancer.
En août 2009, «The New England Journal of Medicine» a publié les résultats de l’étude pivot BIG 1-98 qui démontrent que l’utilisation de Femara pendant cinq ans après l'intervention chirurgicale constituait une approche optimale chez les femmes postménopausées atteintes d’un cancer du sein hormono-dépendant précoce.

In August, “The New England Journal of Medicine” published results from the landmark BIG 1-98 study affirming the five-year upfront use of Femara after surgery was an optimal treatment approach versus tamoxifen for postmenopausal women with early-stage, hormone-receptor positive breast cancer.
En août, «The New England Journal of Medicine» a publié les résultats de l’étude pivot BIG 1-98 qui démontrent que l’utilisation de Femara pendant cinq ans après l'intervention chirurgicale constituait une approche optimale par rapport au tamoxifène chez les femmes ménopausées atteintes d’un cancer du sein hormonodépendant précoce.

44. Olsen A, Njor HS, Vejborg I, Schwartz W, Dalgaard P, Jensen M-B, et al. Breast cancer mortality in Copenhagen after introduction of mammography screening: cohort study.
43. Olsen A, Njor HS, Vejborg I, Schwartz W, Dalgaard P, Jensen M-B, et al. Breast cancer mortality in Copenhagen after introduction of mammography screening: cohort study.